Loading
A phase 3 trial of Bevacizumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Prestige Biopharma Limited, active and no longer recruiting.
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03390686 by Prestige Biopharma Limited, with 650 participants enrolled, started 2019-11-15 and due to reach its primary completion in 2024-07-01. Interventions recorded: Bevacizumab, HD204, Carboplatin, Paclitaxel. Conditions listed: Lung Cancer, Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/